CDTX Key Statistics, Chart & Performance
The current stock price of CDTX is 220.375 USD. In the past month the price increased by 105.56%. In the past year, price increased by 862.37%.
CDTX Latest News, Press Relases and Analysis
CDTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.51 | 392.58B | ||
| AMGN | AMGEN INC | 14.51 | 170.86B | ||
| GILD | GILEAD SCIENCES INC | 15 | 152.43B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.1 | 114.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.47 | 77.91B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 787.22 | 53.04B | ||
| INSM | INSMED INC | N/A | 41.38B | ||
| NTRA | NATERA INC | N/A | 31.50B | ||
| BIIB | BIOGEN INC | 10.43 | 25.61B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.72 | 21.28B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.24B | ||
| INCY | INCYTE CORP | 14.72 | 18.55B |
Related stock screener links
About CDTX
Company Profile
Cidara Therapeutics, Inc. engages in developing targeted immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. The company is headquartered in San Diego, California. The company went IPO on 2015-04-15. The firm is using its Cloudbreak platform to develop drug-Fc conjugate (DFC), immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. The Company’s Cloudbreak platform enables development of DFCs that inhibit specific disease targets while simultaneously engaging the immune system. The Company’s lead DFC candidate CD388, is a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which has completed Phase I and Phase IIa clinical trials. Its oncology DFC candidate, CBO421, is a development candidate targeting CD73 for the treatment of solid tumors. Its Cloudbreak platform creates single molecule cocktails by coupling targeted small molecules and peptides to a human antibody fragment (Fc). The firm is also advancing multiple preclinical and discovery programs targeting cancer and autoimmune diseases.
Company Info
CIDARA THERAPEUTICS INC
6310 Nancy Ridge Dr Ste 101
San Diego CALIFORNIA 92121 US
CEO: Jeffrey Stein
Employees: 38
Phone: 18587526170
CIDARA THERAPEUTICS INC / CDTX FAQ
What does CIDARA THERAPEUTICS INC do?
Cidara Therapeutics, Inc. engages in developing targeted immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. The company is headquartered in San Diego, California. The company went IPO on 2015-04-15. The firm is using its Cloudbreak platform to develop drug-Fc conjugate (DFC), immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. The Company’s Cloudbreak platform enables development of DFCs that inhibit specific disease targets while simultaneously engaging the immune system. The Company’s lead DFC candidate CD388, is a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which has completed Phase I and Phase IIa clinical trials. Its oncology DFC candidate, CBO421, is a development candidate targeting CD73 for the treatment of solid tumors. Its Cloudbreak platform creates single molecule cocktails by coupling targeted small molecules and peptides to a human antibody fragment (Fc). The firm is also advancing multiple preclinical and discovery programs targeting cancer and autoimmune diseases.
Can you provide the latest stock price for CIDARA THERAPEUTICS INC?
The current stock price of CDTX is 220.375 USD. The price increased by 0.08% in the last trading session.
What is the dividend status of CIDARA THERAPEUTICS INC?
CDTX does not pay a dividend.
How is the ChartMill rating for CIDARA THERAPEUTICS INC?
CDTX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the Price/Earnings (PE) ratio of CIDARA THERAPEUTICS INC (CDTX)?
CIDARA THERAPEUTICS INC (CDTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.78).
Can you provide the number of employees for CIDARA THERAPEUTICS INC?
CIDARA THERAPEUTICS INC (CDTX) currently has 38 employees.
Can you provide the short interest for CDTX stock?
The outstanding short interest for CIDARA THERAPEUTICS INC (CDTX) is 10.6% of its float.
CDTX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CDTX. When comparing the yearly performance of all stocks, CDTX is one of the better performing stocks in the market, outperforming 99.77% of all stocks.
CDTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CDTX. CDTX has a great financial health rating, but its profitability evaluates not so good.
CDTX Financial Highlights
Over the last trailing twelve months CDTX reported a non-GAAP Earnings per Share(EPS) of -11.78. The EPS decreased by -70.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.62% | ||
| ROE | -43.74% | ||
| Debt/Equity | 0 |
CDTX Forecast & Estimates
15 analysts have analysed CDTX and the average price target is 220.19 USD. This implies a price decrease of -0.08% is expected in the next year compared to the current price of 220.375.
For the next year, analysts expect an EPS growth of 27.77% and a revenue growth -100% for CDTX